Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02214615 · ClinicalTrials.gov registry record · Phase 4
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations
A Phase 4 study, sponsored by VA Connecticut Healthcare System.
- Completed
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT02214615: Completed Phase 4 study, sponsored by VA Connecticut Healthcare System.
NCT02214615 is a Phase 4 study that has completed, run by VA Connecticut Healthcare System. The registered enrollment target is 2 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02214615, a Phase 4 study, has completed, sponsored by VA Connecticut Healthcare System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
This research study is designed to investigate brain response using fMRI scan, and behavioral responses, to treatment with the drug carbamazepine (CBZ) in patients with the painful sodium channelopathy inherited Erythromelalgia (IEM). This study is designed to identify the central nervous system (CNS) regions that are activated during ongoing or evoked pain attacks, and the altered CNS response to CBZ treatment. This will advance our understanding of how IEM affects the brain. We also hope to validate a pharmacogenic approach to the study of IEM by use of an FDA approved drug. We hope, but cannot be sure, that subjects will directly benefit from this study.
Interventions
- DRUG Placebo
- DRUG Carbamazepine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-07 |
| Phase | Phase 4 |
What the finished NCT02214615 record still lists
NCT02214615 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02214615 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02214615 about?
NCT02214615 is a clinical study titled "Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations". This research study is designed to investigate brain response using fMRI scan, and behavioral responses, to treatment with the drug carbamazepine (CBZ) in patients with the painful sodium channelopathy inherited Erythromelalgia (IEM). This study is designed to identify the central nervous system (CN...
What is the current status of trial NCT02214615?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2014-04. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02214615?
The interventions under investigation include: Placebo (DRUG), Carbamazepine (DRUG).
Who is sponsoring clinical trial NCT02214615?
This trial is sponsored by VA Connecticut Healthcare System, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02214615's enrollment target sits among peer trials
2 1998th of 2000 higher than 1 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia